Trial Outcomes & Findings for Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma (NCT NCT03120676)

Last Updated: 2019-11-14

Results Overview

The primary endpoint will be computed as proportions along with exact 95% confidence intervals.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

3 participants

Primary outcome timeframe

12 months

Results posted on

2019-11-14

Participant milestones
Measure	Atezolizumab Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles. Atezolizumab: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
Overall Study STARTED	3
Overall Study COMPLETED	2
Overall Study NOT COMPLETED	1

Reasons for withdrawal
Measure	Atezolizumab Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles. Atezolizumab: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
Overall Study Not treated	1

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Baseline characteristics by cohort
Measure	Atezolizumab n=3 Participants Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles. Atezolizumab: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
Age, Continuous	33 years n=99 Participants
Sex: Female, Male Female	1 Participants n=99 Participants
Sex: Female, Male Male	2 Participants n=99 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=99 Participants
Race (NIH/OMB) Asian	0 Participants n=99 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=99 Participants
Race (NIH/OMB) Black or African American	0 Participants n=99 Participants
Race (NIH/OMB) White	2 Participants n=99 Participants
Race (NIH/OMB) More than one race	0 Participants n=99 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=99 Participants
Region of Enrollment United States	3 Participants n=99 Participants

Timeframe: 12 months

Population: Data not collected

The primary endpoint will be computed as proportions along with exact 95% confidence intervals.

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Memorial Sloan Kettering Cancer Center

Phone: 212-639-5059